Saroglitazar is primarily used in the management of type 2 diabetes mellitus, especially in patients with diabetic dyslipidemia. It helps in improving glycemic control by reducing blood glucose levels and also addresses abnormal lipid levels by lowering triglycerides and increasing HDL cholesterol. Due to its dual action on glucose and lipid metabolism, it is beneficial in patients with metabolic syndrome. It is particularly prescribed when standard therapies are insufficient in controlling both hyperglycemia and hypertriglyceridemia. Additionally, it has shown potential in improving liver function parameters, making it useful in the treatment of non-alcoholic steatohepatitis (NASH).